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Metastatic neoplasms to the ovary often cause diagnostic problems, in particular those large ovarian masses
mimicking primary tumors. Most of these tumors arise from digestive system or breast, while 37-year-old woman
diagnosed as right adnexal complex mass, with a subpleural nodule in the apical part of the left lower lobe, at
preoperative chest computed tomography scan. The patient underwent total abdominal hysterectomy with right
salpingo-oophorectomy (ovarian mass 220 × 200 mm), total omentectomy, left ovarian biopsy, peritoneal random
biopsies, and peritoneal washings for cytology. Pathologic and immunohistochemical examination of ovarian
specimen suggested morphology and expression of metastatic lung adenocarcinoma with an intense positivity for
Thyroid Transcriptional Factor-1 (TTF-1) and Cytokeratin 7 (CK7) staining. Fine needle biopsy of the lung nodule
found epithelioid like malignant cells, confirming the diagnosis of an ovarian metastasis from a primary lung cancer.
This report focused on the clinical and pathologic diagnostic challenge of distinguishing secondary from primary
ovarian neoplasms. Issues on useful immunohistochemical stains are also discussed.
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Ovarian complex masses are generally primary carcinoma
and less frequently metastasis from extra-gynecological tu-
mors, such as the stomach, colon, breast, pancreas, kidney
adenocarcinomas. The occurrence of ovarian metastasis
has been reported in a range from 6% to 22%. Most of
them are represented by gastrointestinal secondarism [1].
Ovarian metastasis from lung cancer represents only 2-4%
of all ovarian metastatic masses [2]. Because of different
treatment and prognosis, distinguishing between a primary
and metastatic ovarian neoplasm is crucial for correct
therapeutic strategy.
In the presence of synchronous tumors, imaging tech-
niques (ultrasound, computed tomography, magnetic
resonance), and even conventional morphology are often
inadequate for reliable diagnosis. In these circumstances
the use of appropriate immunohistochemical markers is
able to provide additional evidence to differentiate pri-
mary from metastatic neoplasms.* Correspondence: monicantile@libero.it
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reproduction in any medium, provided the orWe report a rare case of lung adenocarcinoma with me-
tastasis to the ovary, as the only extra-thoracic localization,
and we discuss the clinic-pathologic diagnostic issues in
the differential diagnosis, with particular regard to immu-
noistochemical staining.Case presentation
A 37-year-old woman was admitted to Department of
Gynaecologic Oncology in March 2009 for a fast-growing
pelvic mass and increased serum levels of tumor markers.
Her personal oncological history has been characterized
by a 1,4 mm melanoma in the left scapular region skin
evidenced during the last year, with negative sentinel
lymph node and no indications to any postoperative treat-
ment. The patient had undergone appendectomy at the
age of 19, and did not have a history of smoking or radi-
ation. Recent Pap-Smear, mammography, and breast ultra-
sound were negative.
Preoperative work-up included: gynecological examin-
ation, transvaginal ultrasound (TVUS), chest-abdomen-
pelvis computed tomography (CT) scan, colonoscopy,
tumor marker serum levels (CEA, TPA, CA15.3, CA125).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complex mass (154×108×142 mm) with a necrotic colli-
quative central area and a solid peripheral area, displacing
ileum and left colon; some aortic lymph node swellings
(maximum diameter 14 mm); solid inhomogeneous par-
enchymal lung tissue in the left lower lobe with irregular
shape and pleural projections (44×27 mm); another
subpleural nodule in the apical part of the left lower lobe
(10 mm) (Figure 1).
Gynecological examination an TVUS confirmed the pres-
ence of a gross pelvic mass, likely originating from the
adnexa. Colonoscopy was negative for infiltration or endo-
luminal lesions. Tumor marker serum levels were abnor-
mal: CEA 264.9 ng/ml, TPA 113.0 U/l, CA15.3 499.1 U/ml,
CA125 50.5 U/ml.
Therefore, a total body fluorodeoxyglucose - positron
emission tomography (FDG-PET) without evidence of
accumulation areas further than the abdominal pelvic
and lung lesions already described at imaging.
The patient underwent laparotomy with evidence of
20 cm cystic mass arising from right ovary, no lesions of
other ovary, nor in the peritoneal cavity; the following
procedures were done: total hysterectomy, right salpingo-
oophorectomy, total omentectomy, other ovarian peri-
toneal random biopsies, and peritoneal washings for
cytology.
Intraoperative frozen sections pathology showed a
moderately to poorly differentiated, primary or meta-
static ovarian adenocarcinoma. Final pathology revealed:
22×20 cm cystic mass from the right ovary with intact
capsule and smooth outer surface; the cut surface
showed an outlying yellow-pinkish zone with a centralFigure 1 Abdominal-pelvic CT scan (left): parauterine complex mass w
(154×108×142mm); thoracic CT scan (right): solid inhomogeneous pa
pleural projections (44×27mm).yellowish fluid, and the gross appearance at cut section
was a peripheral solid and whitish rim, with central
cystic space mucus containing (Figure 2); peritoneal
cytology, omentum, other ovary, and peritoneal random
biopsies negative for malignant cells.
The surgical specimens were fixed in 10% neutral-
buffered formalin, routinely processed, and embedded in
paraffin. For the light microscopic examination, ovarian
tissue sections were cut at a thickness of 4 μm and con-
ventionally stained with hematoxylin and eosin (H&E),
periodic acid-Schiff (PAS), and mucicarmin / Alcian blue
stains. These histologic permanent sections showed a
moderately differentiated papillary adenocarcinoma, with
diffuse ovarian cortex infiltration and extensive central
necrosis (Figures 3, 4). No resemblance with any con-
ventional primary ovarian adenocarcinoma (serous papil-
lary, endometrioid, clear cell) was observed.
Immunohistochemistry (IHC) was performed on the
4 μm thick paraffin sections with the avidin-biotincomplex
immunoperoxidase technique, using a DAKO Auto Stainer
(DAKO, Carpinteria, CA, USA), with EnVision polymer
(DAKO, Carpinteria, CA, USA) and specific antibodies
(anti-CK7, -TTF-1, -WT-1, -CK20, -CA19-9, -p16). The
antigen antibody immunoreaction was visualized using
diaminobenzedine (DAB) as a chromogen, and the slides
were counterstained with Mayer’s hematoxylin. So, IHC
on ovarian specimen was performed: intense positivity for
TTF-1 and CK7 staining was found, while WT-1, CK20,
CA19-9, and p16 were negative. In particular, a deep ex-
pression of TTF-1 and a WT-1 negativity in all neoplastic
cells was observed (Figures 5, 6). So, diagnosis of ovarian
metastasis from lung adenocarcinoma was suggested.ith necrotic colliquative central area and solid peripheral area
renchymal lung tissue in left lower lobe with irregular shape and
Figure 2 Ovarian metastasis from lung adenocarcinoma: Gross appearance of peripheral solid and whitish rim, with central cystic
space mucus containing (cut section).
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one week from surgery the patient was discharged with
an adjuvant chemotherapy program. A partial response
was achieved after six cycles of carboplatin (AUC 6) and
paclitaxel (175 mg/mq) plus bevacizumab (7.5 mg/mq)
at day 1 every 21 days, followed by a maintenanceFigure 3 Ovarian metastasis from lung adenocarcinoma: Diffuse ovar
adenocarcinoma (hematoxylin and eosin, original magnification 50×)therapy with bevacizumab (7.5 mg/mq) every 21 days
(stopped for allergic reaction). Afterwards, a stereotaxic
radiation therapy was given to the lung lesions (10 Gy
in 5 doses), with achievement of a complete remission.
In the following ten months there is no evidence of
recurrence.ian cortex infiltration by moderately differentiated
.
Figure 4 Ovarian metastasis from lung adenocarcinoma: Papillary growth pattern; little neoplastic emboli beneath fibrotic capsule
(hematoxylin and eosin, original magnification 250×).
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dule was then performed, showing epithelioid like ma-
lignant cells. This study was approved by the ethics
committee of National Cancer Institute “G. Pascale”.
Discussion
The incidence of secondary metastatic tumors in ovary
is variable, depending on different factors, such as accur-
acy of pathological diagnosis, completeness of staging,
and possible geographical/genetic patterns. In a studyFigure 5 Ovarian metastasis from lung adenocarcinoma: Deep expres
original magnification 250×).realized on a series of 500 consecutive malignant ovarian
neoplasms from Northern America, 17% were metastatic
[3], while, in a study from Turkey [4], 22% of 186 ovar-
ian cancers were metastatic. Finally in a very large Chinese
study, only 10% of 10288 malignant ovarian neoplasms
were metastatic [5].
Ovarian metastases derived from non-gynecologic sites
are eleven times more common than those from female
genital tract organs, with adenocarcinomas of the gastro-
intestinal tract being the most frequent [6]. In a recentsion of TTF-1 in all neoplastic cells (immunohistochemistry,
Figure 6 Ovarian metastasis from lung adenocarcinoma: No expression of WT-1 (immunohistochemistry, original magnification 250×).
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cies and adnexal tumors, 68% of ovarian metastatic
tumors were detected [7].
Such tumors may be the initial manifestation of a pa-
tient’s cancer, often causing the tumor to be mistaken for
a primary ovarian neoplasm, even after microscopic exam-
ination. Indeed, a primary extragenital tumor was identi-
fied only after surgery for an ovarian mass in 17% of cases
in one study [8] and in 38% of patients in another report,
with a time interval ranging from 4 days to 7 months [9].
Bilaterality and multinodularity are cardinal features of
secondary ovarian carcinomas, irrespective of the site of
origin of the primary tumor. In approximately three
fourths of cases, both ovaries are grossly involved, al-
though one of the ovaries may be substantially smaller
than the other. This is in stark contrast to the very high
frequency of unilateral ovarian involvement in primary
ovarian tumors of endometrioid, mucinous, and clear
cell types, with which metastatic tumors are most often
confused. Another feature of secondary ovarian neo-
plasms is the presence of high-stage disease, affecting
multiple peritoneal sites, omentum, and retroperitoneal
lymph nodes [1].
Lung carcinoma rarely metastasizes to the ovary, being
the primary tumor in only 2-4% of ovarian metastases.
Such frequency, however, is increasing due to rising inci-
dence of lung cancer in women [2]. So far, forty cases
are been reported of lung cancer metastatic to the ovary
in an age range of 26 to 76 years [2,10-16]. Small cell
carcinoma and adenocarcinoma were more likely to
present with ovarian manifestations than other subtypes
(small cell carcinoma: 45% (18 of 40); adenocarcinoma:32.5% (13 of 40); large cell carcinoma: 12.5% (5 of 40);
and 2.5% (1 of 40) for squamous cell carcinoma, atypical
carcinoid, bronchiole-alveolar carcinoma, and pulmonary
blastoma). A prior lung carcinoma was documented in
more than half of cases, the lung and ovarian tumors oc-
curred synchronously in one third, and only in the
remaining cases, cancer was first detected in the ovary and
then in the lung. Approximately 30% only of ovarian me-
tastases were bilateral. Interesting to note that a coexisting
primary ovarian tumor was present in 10% (4/40) of cases.
In the case presented, the ovarian tumor size (22×20 cm),
the unilaterality of lesion, the smooth surface with intact
capsule, and the absence of intra-abdominal spread were
all infrequent features for a metastatic pattern.
Morphologically, we were dealing with a moderately
differentiated papillary adenocarcinoma; the papillae and
the variably sized glands were embedded in desmoplastic
stroma and were lined by a single layer of atypical
cuboidal-cylindric cells with apical snouts and huge, hy-
perchromatic nuclei. Differential diagnosis with primary
ovarian carcinoma included the more common histotypes
like serous papillary, endometrioid and clear cell adeno-
carcinoma. Typical broad fibrous papillae and psammoma
bodies of serous papillary adenocarcinoma were absent;
cylindric and sometimes ciliated cells observed in our case
could simulate cells found in endometrioid carcinoma and
apical, buldging nuclei could remember, in some way,
“hobnail nuclei” typical of clear cell carcinoma, but hya-
linized papillae and clear/glycogen rich cytoplasm were
both lacking.
In differential diagnosis, IHC is an important adjunct
to morphology. In our case, immunohistochemical stu-
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negative staining for WT-1, CK20, CA19.9 and p16. So,
primary ovarian neoplasm and ovarian metastasis from
colonic adenocarcinoma could be excluded.
In particular, TTF-1, member of the NKx2 homeo-
domain transcription factor family, is expressed in the
lung and thyroid and widely used in surgical pathology,
also for determining if an adenocarcinoma of unknown
primary is of pulmonary origin [17].
This marker has only been studied in a few gynecologic
neoplasms and reported in 4% of endocervical adenocar-
cinomas, 16% of endometrial endometrioid adenocarcin-
omas, and 23% of endometrial serous carcinomas [18].
Rarely TTF-1 has been found to be expressed in some
ovarian tumors but in a recent study, TTF-1 expression
significantly improved progression-free (p=0.017) and
overall survival (p=0.017), and was identified to be an in-
dependent prognostic factor for ovarian cancer in multi-
variate analysis (p=0.047) [19].
A promising addition on immunohistochemical panel
for identifying metastases from lung cancer could be the
Napsin A, an aspartic proteinase detected in type 2
pneumocytes and alveolar macrophages, and putative
marker for pulmonary adenocarcinomas. Indeed, Napsin
A is useful for distinguishing primary lung adenocarcin-
oma from adenocarcinomas of other organs at primary
and metastatic sites [20], and, in particular, the com-
bined use of Napsin A and TTF-1 increased sensitivity
and specificity for identifying lung origin in the setting
of a metastatic adenocarcinoma [21].
In conclusion, the diagnosis of tumors that secondarily
involve the ovary, so as not to mistake them for primary
ovarian neoplasms, can cause diagnostic problems, even
for experienced gynecologic pathologists and particularly
when the primary site is unknown. Ovarian metastases
can share both gross and microscopic features with pri-
mary ovarian neoplasms, especially for those tumors that
produce large, symptomatic ovarian tumors that mas-
querade clinically and pathologically as primary ovarian
tumors of surface epithelial type [Hart, Vang]. In these
cases, IHC, with selected immunostains, can be an im-
portant adjunctive component in the evaluation of a
neoplasm, whether primary or metastatic, with impor-
tant help to treatment decision making.
Indeed, the current case didn’t show typical clinical
and gross features of metastasis, but histopathologic fea-
tures and immunohistochemical results, notwithstanding
occasionally reported TTF-1 expression in ovarian can-
cer, led us to make the correct diagnosis.
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